Kenny Frazier

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Brian Zambrowicz, J Freiman, Phil Brown et al. · Clinical Pharmacology & Therapeutics · 2012 · 239 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Matthew H. Kulke, Thomas M. O’Dorisio, Alexandria T. Phan et al. · Endocrine Related Cancer · 2014 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome

Philip M. Brown, Douglas A. Drossman, Alastair J.J. Wood et al. · Gastroenterology · 2011 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa et al. · Clinical Therapeutics · 2013 · 78 citations

Medicine, Endocrinology, Pharmacology +17

Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

Brian Zambrowicz, Ike Ogbaa, Kenny Frazier et al. · Clinical Therapeutics · 2013 · 65 citations

Medicine, Endocrinology, Pharmacology +13